Original language | English (US) |
---|---|
Pages (from-to) | 1298-1299 |
Number of pages | 2 |
Journal | JAMA cardiology |
Volume | 2 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2017 |
Funding
completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine